Teva Pharmaceutical Industries Limited Comments on Paragraph IV Filing for COPAXONE(R); Intends to File Lawsuit against Generic Filer for Patent Infringement

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today commented on Momenta Pharmaceuticals, Inc./Sandoz Inc.’s announcement regarding the filing of a Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate), a leading multiple sclerosis therapy.